Search
Methylisothiazolinone
go.drugbank.com/drugs/DB15884InvestigationalSynonyms: N-Methylisothiazolin-3-oneCategories: Compounds used in a research, industrial, or household settingGlyceryl laurate
go.drugbank.com/drugs/DB16635InvestigationalCategories: Compounds used in a research, industrial, or household settingBarbexaclone
go.drugbank.com/drugs/DB09001ExperimentalDespite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalIt has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Cardarine
go.drugbank.com/drugs/DB05416InvestigationalCardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.
Chloride ion
go.drugbank.com/drugs/DB14547InvestigationalMixtures: BION 3 FILM COATED TABLETSynonyms: Chloride ion, Chloride (ion)8-chlorotheophylline
go.drugbank.com/drugs/DB14132ExperimentalBecause adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation. … Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate].
NXN-188
go.drugbank.com/drugs/DB06096InvestigationalNXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalXAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma]. … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].
TAS-106
go.drugbank.com/drugs/DB06656InvestigationalTAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].